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Available online 2 March 2016Background: Earlymorning off (EMO) is a symptom experienced by patients with Parkinson's disease (PD) in any
stage of the illness; however, few studies have explored its prevalence. Thus, the impact of EMO on patient Qual-
ity of Life (QOL) and caregiver burden is unclear.
Materials and methods: A QOL questionnaire was administered to members of the Japan Parkinson's Disease As-
sociation and their caregivers via mail using the PD questionnaire— 8 (PDQ-8), which measures the appearance
of EMO. The analysis assessed the responses from 2205 completed surveys.
Results: Patients who felt they had EMO amounted to 79.8%, with 37.8% of respondents stating that EMO was a
daily occurrence. The prevalence of EMO increased as the Hoehn and Yahr stage increased, but was observed
at a rate of 52.4% even in patients at Stage 1. The QOL of those with EMO was signiﬁcantly reduced
(p b 0.0001), and the odds of caregivers feeling a sense of burden was higher for the group that experienced
EMO even after adjusting for age of patient, age of caregivers, disease duration, relationship to patient, and
Hoehn and Yahr stage.
Conclusion: The prevalence of EMO in the survey results was high, signiﬁcantly lowering the patients' QOL. Inter-
estingly, EMO was also observed in the early stage of the disease. Since the presence of EMO impacts patients'
QOL and caregiver burden, medical intervention and appropriate gathering of information for such intervention
should be considered.
© 2016 Elsevier B.V. All rights reserved.Keywords:
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Parkinson's disease (PD) is the second most prevalent neurodegen-
erative disease, next to Alzheimer-type dementia in the elderly popula-
tion, and in Japan, approximately 141,000 people have been reported to
have PD [1]. It is anticipated that the number of patients will further in-
crease as the Japanese population continues to age rapidly. Recent ad-
vances have been made in pharmacotherapy for patients with PD such
as dopaminergic medications. Because improvements in the accuracy
of PD diagnosis and treatment have led to the life expectancy in patients
with PD being nearly identical to those of healthy individuals, improve-
ment of the quality of life (QOL) is now an important issue while plan-
ning treatment [2]. It is important to ask individual patients about their
anxieties and concerns and have them choose appropriate treatments
because PD is a disease that requires long-term care. Moreover, in
most patients with PD, care becomes necessary in advanced stages. In
such patients with PD, care giving turns into a long-term issue, and
the reduction of caregiver burden is a challenge that should be consid-
ered concurrently with treatment for patients. In the previous-ku, Fukuoka-shi, Fukuoka-ken
.questionnaire survey that was conducted on patients with PD, we
found that approximately 70% of patients experienced periods of time
of insufﬁcient drug efﬁcacy with reduction in QOL, and that more than
half of patients in this groupwere aware of the insufﬁcient drug efﬁcacy
both during the night and early morning [3]. Inappropriate pharmaco-
therapy or insufﬁcient management of wearing-off can frequently lead
to early morning off (EMO). There have been long-acting dopamine ag-
onists that have been available to control symptoms during these night-
time and early-morning periods. Hence, such agonists have garnered
attention in recent years, as it has become possible to cope with night-
time symptoms to a certain degree. Thus, an investigation regarding
the impact of EMOonpatient QOL and caregiver burdenwas conducted.
2. Materials and methods
A countrywide surveywas conducted bymail among 8001members
of the Japan Parkinson's Disease Association. This study was conducted
upon receiving the approval of the Fukuoka University Hospital's Ethics
Committee. When the patient returned the questionnaire, it was taken
as consent to use the patient's data. Two types of questionnaires (one
for patients and one for caregivers) were sent to the members' ad-
dresses, and the questionnaires were returned in the mail after they
had been completed. The survey was conducted from August 13
Table 1
Demographics of patients and caregivers. Data are presented as n (%) unless stated otherwise.
Total sample Patient and caregiver dyads
Patients n= 2632 Caregivers n= 2206 Patients n= 2155 Caregivers n= 2155
Age (mean, sd) 70.7 (7.9) 67.7 (10.7) 70.9 (7.6) 67.7 (10.7)
Gender
Male 1100 (41.8) 967 (43.8) 963 (44.7) 946 (43.9)
Female 1424 (54.1) 1137 (51.5) 1103 (51.2) 1109 (51.5)
Employment
Employed 186 (7.1) 619 (28.1) 144 (6.7) 603 (28.0)
Help with housework 288 (10.9) 64 (2.9) 238 (11.0) 63 (2.9)
Unemployed 2095 (79.6) 1324 (60.0) 1721 (79.9) 1296 (60.1)
Hoehn and Yahr stage
Stage I 76 (2.9) – 48 (2.2) –
Stage II 207 (7.9) – 169 (7.8) –
Stage III 959 (36.4) – 785 (36.4) –
Stage IV 322 (12.2) – 282 (13.1) –
Stage V 92 (3.5) – 86 (4.0) –
Time since ﬁrst diagnosis
b3 years 221 (8.4) – 156 (7.2) –
3–7 years 681 (25.9) – 533 (24.7) –
More than 7 years 1675 (63.6) – 1419 (65.8) –
Parkinsonian medication(multiple answer)
Levodopa 1667 (63.3) – 1355 (62.9) –
Pramipexole IR 1076 (40.9) – 875 (40.6) –
Pramipexole ER 215 (8.2) – 173 (8.0) –
Ropinirole 474 (18.0) – 383 (17.8) –
Cabergoline 294 (11.2) – 246 (11.4) –
Pergolide 294 (11.2) – 245 (11.4) –
Bromocriptine 58 (2.2) – 49 (2.3) –
Entacapone 945 (35.9) – 790 (36.7) –
Selegiline 918 (34.9) – 763 (35.4) –
Zonisamide 460 (17.5) – 380 (17.6) –
Living in same household
Yes – 1967 (89.2) – 1927 (89.4)
Relationship to patient
Spouse – 1753 (79.5) – 1717 (79.7)
Child – 214 (9.7) – 205 (9.5)
Parent – 92 (4.2) – 91 (4.2)
Other family member – 13 (0.6) – 12 (0.6)
Others – 31 (1.4) – 29 (1.3)
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gender, work situation, Hoehn and Yahr stages [4], disease duration
from the onset, pharmaceuticals used, QOL (Parkinson's disease
questionnaire-8: PDQ-8) [5,6], whether they had experienced EMO, fre-
quency of EMO (days/week), and problems due to EMO. The questions
in the survey for caregivers included age, gender, work situation,
whether they were living with the patient, relationship to the patient,
sense of burden for giving care (independent questionnaire listed
below), whether their patient had experienced EMO, frequency of
EMO (days/week), and problems due to EMO.
The possible responses regarding the sense of burden for giving care
were as follows: never, once in a while, sometimes, frequently, and al-
ways. The individual questionnaire asked caregivers to respond to the
following issues:
1. Cannot go out
2. Feeling the responsibility of needing to provide care and experienc-
ing anxiety
3. Feeling depressed
4. Feeling easily fatigued
5. Being unable to concentrate on work or hobbies and pleasure
6. Feeling anxiety about life in the future
7. Unable to have enough time for yourself
8. Feeling like care giving is worsening your physical condition.
The patients who answered “yes” to the question of “do you feel like
your bodily movements are poor when you wake up?”were deﬁned as
having EMO. The caregivers who answered “yes” to the question of “do
you feel like the bodily movements of the family member with PD are
poor when they wake up?” were deﬁned as having experienced EMO.The PDQ-8 calculates the respondents' PDQ-8 summary index (PDQ-8-
SI). The descriptive statistics were determined by whether the symp-
toms were present when waking up. Student t-test was used to com-
pare the average values of the PDQ-8-SI. Caregiver burden was
categorized as being “present” if the caregiver answered “sometimes”,
“frequently”, or “always”, and categorized as “not present” if the care-
giver answered “never” or “once in awhile.” Then, the descriptive statis-
tics were derived by category for each of the question items. Fisher's
exact test was used to examine the association between the treatment
type and the prevalence of EMO. The univariate logistic regression anal-
ysis was used to investigate the inﬂuence of the absence or presence of
EMO and the level of severity on the Hoehn and Yahr scale (stage III or
higher, or stage II or lower) on caregiver burden. Furthermore, the fol-
lowing variables were adjusted in the multivariate logistic regression
analysis for EMO as a confounding factor: age of patient, age of care-
givers, time since ﬁrst diagnosis, relationship to patient, and Hoehn
and Yahr stage. The signiﬁcance level for all of these analyses was
taken to be 5% for both sides. Statistical analyses were performed with
SPSS version 22.0 for Windows (IBM Japan, Tokyo, Japan).
3. Results
Responseswere received from2632 patientswith PD and 2206 care-
givers during the survey period and there were 2155 cases where re-
sponses were received from both patient and caregiver. The
backgrounds of patients and caregivers are shown in Table 1 (Data ex-
cluding persons with missing data on each questionnaire). The average
patient age was 70.7 ± 7.9 years, and 54.1% of patients were women. In
terms of the Hoehn and Yahr scale, stage III was the most prevalent at
Fig. 1. Prevalence of early morning off (EMO). The frequency of EMO in patients with Parkinson's disease is shown according to the classiﬁcation on the Hoehn and Yahr scale of severity.
There is an astonishing level of common awareness demonstrated between patients and caregivers. Moreover, it should be noted that there is an unexpectedly high frequency of EMO in
non-severe stage I and II patients. One of the causes of this is believed to be insufﬁcient treatment.
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amount of time with the illness was 7 or more years with a response
rate of 63.6%. The average age of the caregivers was 67.7 ± 10.7 years.
Caregivers were 51.5% women, and their family relationship with the
person with PD was 79.5% spouses, 9.7% parents, and 4.2% children. A
signiﬁcant number (89.2%) of these caregivers lived together with the
patient.
EMO was observed in 79.8% of all patients, and 52.4% of patients
were at Stage I on the Hoehn and Yahr scale. The percentage of care-
givers who responded that they had experienced EMO was 68.7% and
this was around 10% lower than patients who responded that they
had EMO (Fig. 1). Among those reporting that EMO occurred daily,
37.8% were patients and 33.9% were caregivers. Among those under
Stage I on the Hoehn and Yahr scale, 26.2% of patients, and 14.3% of
their caregivers responded that they experienced EMO every day.
Among the respondents who answered that they had EMO, the troubles
caused by EMO for patients were “difﬁculties changing clothes” 68.0%,
“difﬁculties using the bathroom” 44.2%, “being unable to be active in
themorning” 42.9%, “difﬁculties havingmeals” 35.0%, “being a nuisance
to the family” 31.2%, and “waking up with pain” 17.3%. The troubles
caused by EMO for caregivers were “assisting in changing clothes”
47.0%, “assistance with the bathroom” 28.8%, “being unable to be active
in the morning” 27.5%, “being unable to go out” 26.7%, “providingTable 2
Comparison of PDQ-8-Summary Index between patient groups with and without EMO.
Total Patients with EMO Patients without
EMO
p value⁎
n PDQ-8-SI n PDQ-8-SI n PDQ-8-SI
Total 1976 40.0 ± 20.9 1496 42.3 ± 20.2 387 30.7 ± 20.1 b0.0001
Hoehn &Yahr stages
Stage I 47 25.7 ± 18.7 22 33.1 ± 16.6 20 16.7 ± 18.6 0.0044
Stage II 156 34.4 ± 19.9 114 39.0 ± 19.3 40 22.7 ± 16.4 b0.0001
Stage III 740 37.4 ± 17.8 577 38.9 ± 17.8 131 31.7 ± 15.9 b0.0001
Stage IV 264 49.1 ± 19.3 221 50.4 ± 19.4 35 39.4 ± 16.3 0.0017
Stage V 72 66.2 ± 23.4 48 67.1 ± 20.7 13 57.2 ± 32.4 0.1828
Data excluding 178 patients without response on PDQ-8-Summary Index and 93 patients
without response on experienced EMO. Data are expressed as numbers of patients, mean
± SD, or p values.
⁎ Student t-test (comparison between the two groups).assistance with meals” 26.0%, and “providing assistance with taking
medicine” 19.4%.
The PDQ-8-SI score for the group with EMO was 42.3 ± 20.2, while
the score for the group without EMO was 30.7 ± 20.1. Thus, a compar-
ison shows that the PDQ-8-SI score for the group with EMO was signif-
icantly higher than that of the group without EMO (Table 2). According
to the Hoehn and Yahr stages, the group with EMO had a signiﬁcantly
worse QOL for people in stages I–IV. The questions on caregiver burden
that had the highest percentages were “feeling anxiety about life in the
future” 57.0%, “feeling the responsibility of needing to provide care and
experiencing anxiety” 50.5%, and “being unable to have enough time for
one's self” 46.8%. When the odds were calculated for the inﬂuence of
EMO on caregiver burden, the caregiver burden was increased for all
of the items in the group with EMO. To remove the inﬂuence of age of
patient, age of caregivers, disease duration, relationship to patient, and
Hoehn and Yahr stage on caregiver burden, multivariate logistic regres-
sion analysis was used and the adjusted odds ratio was calculated
(Table 3). Thus, EMO has independent impact on all the caregiver bur-
den parameters.
4. Discussion
This survey clariﬁed the real conditions of EMO for patients with PD
and the burden on caregivers that it causes. EMO was observed in ap-
proximately 80% of patients. It should be noted that approximately
50% of patients under stage I on the Hoehn and Yahr stage experienced
EMO, and as the level of severity increased, the percentage of patients
with EMO increased. The frequency of EMO did not depend on the
level of severity, and approximately half of patientswith EMO answered
that they experienced it every day. Thus, our survey showed that EMO
occurswith a high degree of frequency. There has been little research fo-
cusing on EMO; however, according to a report by Chapuis et al., early-
morning akinesia was observedwith a frequency of 58.5% [7]. In the on-
going observational study being conducted by Rizos et al., it has been
observed at a frequency of 61.0% [8]. Moreover, Rizos et al. are
conducting an examination of EMO according to the level of severity
of PD. This study reports that EMO occurs at a rate of 47.7% for mild
cases (Stage 1–2.5 on the Hoehn and Yahr scale), 68.8% for moderate
cases (Stage 2.5–3 on the Hoehn and Yahr scale), and 61.8% for severe
cases (Stage 4–5 on the Hoehn and Yahr scale) [8]. While there are
Table 3
Caregiver burden and its relation to PD severity of the patient and presence of EOM.
Dependent variables Severity of PD (vs. b3 H&Y) With EMO (vs. without EMO)
Univariate Univariate Multivariatea
OR 95%CI p-Value OR 95%CI p-Value OR 95%CI p-Value
Cannot go out 1.75 1.27, 2.42 b0.001 2.09 1.59, 2.74 0.000 1.73 1.19, 2.49 0.004
Feeling the responsibility of needing to provide care and experiencing anxiety 1.77 1.31, 2.40 b0.001 2.25 1.76, 2.88 0.000 1.98 1.40, 2.79 0.000
Feeling depressed 1.83 1.34, 2.50 b0.001 1.88 1.46, 2.42 0.000 1.73 1.22, 2.47 0.002
Feeling easily fatigued 2.12 1.55, 2.89 b0.001 2.13 1.66, 2.74 0.000 1.92 1.35, 2.73 0.000
Being unable to concentrate on work or hobbies and pleasure 2.19 1.59, 3.01 b0.001 1.92 1.48, 2.47 0.000 1.75 1.23, 2.50 0.002
Feeling anxiety about life in the future 1.59 1.18, 2.14 0.002 2.14 1.69, 2.72 0.000 2.26 1.61, 3.17 0.000
Unable to have enough time for yourself 1.96 1.44, 2.66 b0.001 1.83 1.43, 2.34 0.000 1.53 1.09, 2.17 0.015
Feeling like care giving is worsening your physical condition 2.01 1.39, 2.90 b0.001 1.90 1.42, 2.55 0.000 1.70 1.70, 1.12 0.012
OR: odds ratio, 95% CI: 95% conﬁdence interval.
a Adjusted for age of patient, age of caregivers, time since ﬁrst diagnosis, relationship to patient, and Hoehn and Yahr stage.
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methods used, EMO has a higher rate of occurrence in patients with PD.
This study has conﬁrmed that this is the same for patients with early
stage PD. Moreover, approximately 70% of caregivers answered that
they have dealt with EMO, and many caregivers are aware of EMO. On
the other hand, the caregivers' responses that indicated they have
dealt with EMO were approximately 10% less than the patients' re-
sponses. Thus, it is essential to consider that the percentage of patients
who are self-conscious of EMO exceeds the percentage of caregivers
who objectively observe EMO. In the research conducted by Stacy
et al. on patients with PD who have had the disease for b5 years, the
percentage of wearing-off that could be detected from interviews was
29.4%. However, when using a self-administered patient questionnaire
known as the Wearing-off Questionnaire (WOQ), wearing-off was de-
tected at a rate of 57.1%. Thus, this research describes the necessity of
tools to accurately grasp the patient's subjective symptoms [9].
One problem that is caused by EMO is the appearance of dystonia
that occurs when the concentration of anti-Parkinson's drugs in the
serum is reduced. This is painful and can cause sleep disorders, and is
known to be an issue that requires caregiver attention [10,11]. In this
study, however, only approximately 10% of respondents answered
that they “woke up due to pain” as a result of EMO. Nevertheless, the
percentages of people who answered that EMO caused “difﬁculties
changing clothes,” “difﬁculties using the bathroom,” and “being unable
to be active in the morning” was quite high; thus, it became apparent
that patients felt that EMO was a problem that impacted activities of
daily living (ADL) more than it caused a sleep disorder. There was a
higher percentage of patients in the early stages of PD who responded
that they were “unable to be active in the morning” similar to patients
in advanced stages, and the impact that this has on social activities
like work and housework is consequently a problem. Moreover, this
survey showed that the PDQ-8-SI scores were higher for the group of
patients with EMO than they were for the group without EMO; this
demonstrates that EMO has an impact on the patients' QOL. We found
only a correlation between EMO and the dopamine agonist (DA)
usage from the patient answers (rate of DA usage: with EMO, 63.8%;
without EMO, 58.0%; p=0.045).When considering EMOwith patient's
level of severity, the group with EMO had a signiﬁcantly worse QOL for
people in stages I–IV on the Hoehn and Yahr scale. Chapuis et al. have
identiﬁed the impact of early-morning akinesia on QOL [7]. Factors
that have been reported to lower the QOL of patients with PD are the
level of severity on the Hoehn and Yahr stage [11], uniﬁed Parkinson's
disease rating scale (UPDRS) score [12], longer disease duration [13,
14], and presence of depression as a complication [15,18–20]. In addi-
tion, Rizos et al. demonstrated that EMOwas also associatedwith signif-
icant non-motor off symptoms including urinary urgency, anxiety,
dribbling of saliva, pain, low mood, limb paresthesia, and dizziness in
88% of patients [21]. We calculated the odds ratio to conﬁrm the corre-
lation of EMO with the presence of depression. We found a correlationbetween EMO and the presence of depression (OR: 2.027, 95% CI:
1.600–2.568, p b 0.001).
Moreover, EMO is also believed to be a cause of deterioration of the
patient's QOL, and it is necessary to gather appropriate information re-
garding it and to provide treatment intervention. In recent years, long-
acting dopamine agonists have been released in the market, and it has
been reported that these improve nighttime sleep disorders and early
morning motor symptoms [16]. This is believed to be one of the poten-
tial treatment options.
This survey clariﬁes that EMO increases the burden on caregivers.
There are several reports concerning the factors that cause an increase
in the burden on caregivers. Carter et al. have reported that as the
level of severity of PD increases, the burden placed on the caregivers in-
crease and the health of the caregivers themselves is threatened [17].
Pal et al. have reported that the duration that the patient has had the
disease, presence of depression, and decline in cognitive function are
all factors that increase the burden on the caregiver and the possibility
that the caregiver will also become depressed [18]. In this study as
well, the odds ratio for the caregiver burden for all of these items in-
creased from approximately 1.6–2 when comparing the patients at
stage III or higher with those at stages lower than stage III. Accordingly,
the patient's level of severity is suggested to be a factor thatmakes care-
giver burden worse. To remove the inﬂuence of age of patient, age of
caregivers, disease duration, relationship to patient, and Hoehn and
Yahr stage, an adjusted odds ratio was calculated using themultivariate
logistic regression analysis. Evenwith this adjusted odds ratio, EMO sig-
niﬁcantly increased the caregiver burden; therefore, it is believed that
EMO causes an impact on caregiver burden independent of the patient's
level of severity. As PD progresses, the role of the caregiver becomes
more important. In this survey, spouses accounted for approximately
80% of caregivers, and the average age of the caregivers was
67.7 years. This clearly shows that in the current survey,most caregivers
are also aged. Many caregivers suffer from depressive tendencies due to
the anxiety associated with providing care with an uncertain future. Pe-
ters et al. have reported that while the physical health of caregivers for
people with PD is not different from the average population of the same
age range, their emotional health is lower than the average population
[19]. There is a correlation between caregiver burden, depression, and
QOL [20], and it is essential for long-term treatment strategies of PD to
take into consideration not only the QOL of patient but also the emo-
tional health and QOL of the caregiver. Therefore, strategiesmust be im-
plemented to reduce caregiver burden.
5. Conclusion
The results of this survey have revealed that EMO is highly prevalent
according to both patients and caregivers. EMOaffects the patient's ADL,
and it lowers their QOL. Moreover, since this could cause an increase in
caregiver burden, consideration for caregiver burden should be taken
5R. Onozawa et al. / Journal of the Neurological Sciences 364 (2016) 1–5during medical intervention and appropriate gathering of information
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